Obesity and Cancer: A Link Too Often Missed

2 days ago
2 min read

Evidence from the IARC and Oxford Oncology shows that obesity is a major and underrecognized oncological risk factor. What does this mean for clinical practice?

When clinicians think about modifiable cancer risk factors, smoking is almost always the first to come to mind. But a growing body of evidence demands that obesity take its place alongside it. According to the International Agency for Research on Cancer (IARC), overweight and obesity are now linked to at least 13 distinct types of cancer, together accounting for approximately 40% of all cancer diagnoses in the United States alone.

This is not a peripheral finding. It is a call to integrate systematic obesity assessment into oncological and preventive care.

The 13 Cancers Linked to Obesity

Following a comprehensive review of more than 1,000 epidemiological studies, the IARC Working Group identified consistent evidence linking excess adiposity with the following malignancies:

• Colorectal cancer

• Breast cancer (postmenopausal)

• Endometrial cancer

• Kidney cancer (renal cell carcinoma)

• Liver cancer (hepatocellular carcinoma)

• Pancreatic cancer

• Esophageal cancer (adenocarcinoma)

• Stomach (gastric) cancer

• Ovarian cancer

• Gallbladder cancer

• Thyroid cancer

• Multiple myeloma

• Meningioma

The biological mechanisms underlying these associations are multifactorial, involving chronic low-grade inflammation, dysregulation of insulin and IGF-1 signalling, altered sex hormone metabolism, and adipokine imbalance - all of which collectively promote a tumorigenic microenvironment.

The Clinical Gap: Obesity Remains Underdiagnosed

Despite the strength of this evidence, obesity is systematically underestimated in oncology settings. A landmark study from the University of Oxford analysing data from more than 79,000 cancer patients across 13 cancer types revealed a striking discrepancy:

Only 26.4% of cancer patients were classified as obese at the time of treatment initiation, yet lifetime obesity prevalence across the same cohort was 53.5%.

On average, lifetime obesity prevalence was 28 percentage points higher than prevalence recorded at treatment initiation. This suggests that a single BMI measurement at diagnosis substantially underestimates a patient’s actual exposure to obesity-related oncological risk.

This has direct implications for prognostication, personalised risk stratification, and follow-up care. Physicians who rely solely on BMI at diagnosis may be working with an incomplete picture.

What This Means for Clinical Practice

The evidence supports a shift toward routinely incorporating obesity history into oncological assessment. Practical recommendations include:

• Documenting longitudinal weight history, not just current BMI, in cancer risk evaluations.

• Using waist-to-height ratio alongside BMI - evidence suggests it is a stronger predictor of metabolic and cardiovascular risk.

• Considering obesity as a modifiable risk factor during post-treatment surveillance and survivorship planning.

• Engaging multidisciplinary teams - including endocrinologists, nutritionists, and bariatric specialists- in the care of patients with obesity-associated cancers.

• Initiating early conversations about weight management as part of cancer prevention, not only after diagnosis.

Obesity is not a background variable. In the context of cancer, it is an independent risk factor with established biological mechanisms and demonstrable clinical consequences. Recognising it systematically and addressing it proactively is part of delivering evidence-based oncological care.